Drug Development
The infectious disease doctor mining the microbiome for drugs
March 15, 2018How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.
Has DTC in the oncology space kept up with science?
March 08, 2018As oncology drugs save or extend the lives of many more patients than anyone could have imagined a few years ago, a new challenge has emerged in the wake of their approval: Selling them to patients scared about their prognosis and alternately ignorant of and skeptical about recent breakthroughs in treatment.
Five things for pharma marketers to know: Wednesday, February 21, 2018
February 21, 2018AbbVie reports successful elagolix trial; White House touts short-term insurance plans; Mayo Clinic chief to retire.
Five things for pharma marketers to know: Wednesday, February 14, 2018
February 14, 2018IPG 2017 net income drops; Bristol-Myers Squibb inks $1.85 billion deal with Nektar on cancer drug; Merck halts final-stage Alzheimer's drug.
New tactics change clinical trial awareness game
January 17, 2018Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn't overwhelm trial organizers.
Five things for pharma marketers to know: Thursday, January 11, 2018
January 11, 2018Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
Five things for pharma marketers to know: Friday, December 8, 2017
December 08, 2017FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance
First 'Digital Drug' Faces a Second Litmus Test: Improving Adherence
November 20, 2017Technology like this could expand further to form better collaborations between pharma, payers and organized providers.
Five things for pharma marketers to know: Tuesday, November 14, 2017
November 14, 2017FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs
Five things for pharma marketers to know: Friday, September 29, 2017
September 29, 2017Merck to stop developing hep.-C drugs; FDA approves new Lilly breast-cancer drug; California bill would outlaw co-pay cards
Study says drug development costs much less than previously estimated
September 11, 2017New research suggests that the oft-cited $2.6 billion estimate for bringing a drug to market is significantly overstated.
Five things for pharma marketers to know: Friday, April 22, 2016
April 22, 2016AstraZeneca to sequence two million genomes; Valeant considering Perrigo CEO as its new chief executive; AMA and PhRMA each spent $6 million on lobbying
Top 25 orphan drugs, by 2015 global sales
February 22, 2016Roche's Rituxan generated $7.3 billion in sales in 2015, making it the top-selling orphan drug.
